Drug intelligence / Profile preview

rosuvastatin + metformin + sitagliptin + telmisartan + cinnamon + garlic + ginger + methi dana + arjun

Development stage
Preclinical
Lead developer
Hamdard University
Modality
Small Molecules
Administration
Oral
01

Overview

This is an **oral multi-ingredient combination** consisting of four pharmaceutical agents—**rosuvastatin, metformin, sitagliptin, and telmisartan**—along with five traditional herbal and spice ingredients: **cinnamon, garlic, ginger, methi dana (fenugreek seeds), and arjun (Terminalia arjuna bark)**. The pharmaceutical components each have established roles: - **Rosuvastatin** is an HMG-CoA reductase inhibitor (statin) used for lowering cholesterol and reducing cardiovascular risk. - **Metformin** is a biguanide antihyperglycemic agent, primarily used for type 2 diabetes. - **Sitagliptin** is a DPP-4 inhibitor for glycemic control in type 2 diabetes. - **Telmisartan** is an angiotensin II receptor blocker (ARB) used for hypertension. The added botanicals and spices are commonly used in traditional medicine: - **Cinnamon** may lower blood glucose and improve lipid profiles by increasing insulin sensitivity and offering antioxidant effects[2][6]. - **Garlic** is cited for its cardioprotective, lipid-lowering, and metabolism-boosting effects, mainly via modulation of cholesterol and vascular tone[6]. - **Ginger** provides anti-inflammatory and digestive benefits and may improve metabolism and glucose handling[6]. - **Methi dana (fenugreek)** contributes fiber, has modest hypoglycemic effects, and aids digestion[2][8]. - **Arjun (Terminalia arjuna)** is valued as a cardiac tonic in Ayurveda, with evidence supporting cardiac muscle strengthening, cholesterol regulation, antihypertensive, and antioxidative actions[4]. This unprecedented combination is not a standard formulation; no single product with this precise set of constituents is listed in pharmaceutical registries or approved by major regulatory authorities. Such complex combinations raise important questions about safety, drug-drug/herb interactions, efficacy, and quality control.

02

Targets

AMPK (Adenosine monophosphate–activated protein kinase)DPP-4 (Dipeptidyl Peptidase-IV)PPARG (Peroxisome proliferator-activated receptor gamma)HMGCR (3-hydroxy-3-methylglutaryl-coenzyme A reductase)CYP2E1AGTR1 (Angiotensin II Type-1 receptor)

Beyond the preview

Go deeper on rosuvastatin + metformin + sitagliptin + telmisartan + cinnamon + garlic + ginger + methi dana + arjun.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on rosuvastatin + metformin + sitagliptin + telmisartan + cinnamon + garlic + ginger + methi dana + arjun.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call